Vasoactive substance resistance mechanisms in diagnosis and treatment of end-stage liver diseases: Disputes and counter-measurement

Jianjun LIU; Wenkai ZHENG; Jianghong WANG; Yanjun REN; Yan LIU; Lizhen ZHAO

doi:10.3969/j.issn.1001-5256.2022.10.040

Volume 38 Issue 10

Oct. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(10): 2408-2411

PDF( 1753 KB)

Vasoactive substance resistance mechanisms in diagnosis and treatment of end-stage liver diseases: Disputes and counter-measurement

DOI: 10.3969/j.issn.1001-5256.2022.10.040

Department of Gastroenterology, The Second Hospital of Handan City, Handan, Hebei 056001, China

More Information

Corresponding author: ZHAO Lizhen, 834736335@qq.com(ORCID: 0000-0001-9748-2509)
Received Date: 2022-06-14
Accepted Date: 2022-07-25
Published Date: 2022-10-20

Abstract

Abstract

The vasoactive substance resistance (VSR) in the end-stage liver disease (ESLD) refers as the reduction of patients' responsiveness to endogenous and exogenous vasoactive substances, cardiac and vascular excitability, peripheral circulatory dysfunction, but induction of related adverse events. VSR is closely related to pathogenesis and treatment-related ESLD complications. However, to date, there are so many unsolved issues, like 1). The cause and underlying mechanism of VSR in ESLD patients; 2). VSR and ESLD multiple organ damages; 3). The preventive and mitigated measurement of VSR; and 4). VSR vasoactive drug use in ESLD patients. This review discussed and summarized the up to date progress in this field of research and clinical VSR in patients with ESLD, i.e., VRS in ESLD patients, disputes of vasoconstrictor drug therapy in ESLD patients, and future research direction of the field.
- End-Stage Liver Disease,
- Vasoconstrictor Agents,
- Vasodilator Agents

FullText(HTML)

References(27)

References

[1]	LI XY, HUA J. Treatment of hepatorenal syndrome: Vasoconstriction or vasodilation?[J]. J Clin Hepatol, 2020, 36(11): 2419-2422. DOI: 10.3969/j.issn.1001-5256.2020.11.005. 李晓芸, 华静. 肝肾综合征的治疗: 缩血管还是扩血管治疗?[J]. 临床肝胆病杂志, 2020, 36(11): 2419-2422. DOI: 10.3969/j.issn.1001-5256.2020.11.005.
[2]	XU XY, ZHENG YY. Hepatorenal syndrome-vasoconstrictor or vasodilator?[J]. J Clin Hepatol, 2011, 27(8): 801-803, 817. http://lcgdbzz.org/article/id/LCGD201108005 徐小元, 郑颖颖. 肝肾综合征——缩血管还是扩血管?[J]. 临床肝胆病杂志, 2011, 27(8): 801-803, 817. http://lcgdbzz.org/article/id/LCGD201108005
[3]	AMIN AA, ALABSAWY EI, JALAN R, et al. Epidemiology, pathophysiology, and management of hepatorenal syndrome[J]. Semin Nephrol, 2019, 39(1): 17-30. DOI: 10.1016/j.semnephrol.2018.10.002.
[4]	BIGGINS SW, ANGELI P, GARCIA-TSAO G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021, 74(2): 1014-1048. DOI: 10.1002/hep.31884.
[5]	LIU JJ, ZHENG WK, WANG JH, et al. Questioning and clinical practice of the 2021 American Society of Hepatology guidelines for the diagnosis, evaluation and management of ascites and hepatorenal syndrome[J]. Chin J Gastroenterol Hepatol, 2022, 31(2): 121-125. DOI: 10.3969/j.issn.1006-5709.2022.02.001. 刘建军, 郑文凯, 王江红, 等. 对2021年美国肝病学会腹水和肝肾综合征的诊断、评估和管理指南的质疑与临床实践[J]. 胃肠病学和肝病学杂志, 2022, 31(2): 121-125. DOI: 10.3969/j.issn.1006-5709.2022.02.001.
[6]	PIANO S, SCHMIDT HH, ARIZA X, et al. Association between grade of acute on chronic liver failure and response to terlipressin and albumin in patients with hepatorenal syndrome[J]. Clin Gastroenterol Hepatol, 2018, 16(11): 1792-1800. e3. DOI: 10.1016/j.cgh.2018.01.035.
[7]	VELEZ J, THERAPONDOS G, JUNCOS LA. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis[J]. Nat Rev Nephrol, 2020, 16(3): 137-155. DOI: 10.1038/s41581-019-0218-4.
[8]	GINÈS P, SOLÀ E, ANGELI P, et al. Hepatorenal syndrome[J]. Nat Rev Dis Primers, 2018, 4(1): 23. DOI: 10.1038/s41572-018-0022-7.
[9]	Chinese Society of Hepatology and Chinese Society of lnfectious Diseases. Guidelines for diagnosis and treatment of cirrhotic ascites and related complications[J]. J Clin Hepatol, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001.5256.2017.10.003. 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001.5256.2017.10.003.
[10]	SCHRIER RW, ARROYO V, BERNARDI M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis[J]. Hepatology, 1988, 8(5): 1151-1157. DOI: 10.1002/hep.1840080532.
[11]	ADEBAYO D, NEONG SF, WONG F. Refractory ascites in liver cirrhosis[J]. Am J Gastroenterol, 2019, 114(1): 40-47. DOI: 10.1038/s41395-018-0185-6.
[12]	KAZORY A, RONCO C. Hepatorenal syndrome or hepatocardiorenal syndrome: revisiting basic concepts in view of emerging data[J]. Cardiorenal Med, 2019, 9(1): 1-7. DOI: 10.1159/000492791.
[13]	FENG LJ, JIA JD. Consensus and controversy on diagnosis and treatment of complications of liver cirrhosis[J]. Chin Hepatol, 2022, 27(1): 4-8. DOI: 10.3969/j.issn.1008-1704.2022.01.002. 冯丽娟, 贾继东. 关于肝硬化并发症诊治的共识与争议[J]. 肝脏, 2022, 27(1): 4-8. DOI: 10.3969/j.issn.1008-1704.2022.01.002.
[14]	WANG L, LONG Y, LI KX, et al. Pharmacological treatment of hepatorenal syndrome: a network meta-analysis[J]. Gastroenterol Rep (Oxf), 2020, 8(2): 111-118. DOI: 10.1093/gastro/goz043.
[15]	MINDIKOGLU AL, PAPPAS SC. New developments in hepatorenal syndrome[J]. Clin Gastroenterol Hepatol, 2018, 16(2): 162-177. e1. DOI: 10.1016/j.cgh.2017.05.041.
[16]	KIM HY, CHO EJ, CHUN S, et al. Red blood cell alloimmunization in Korean patients with myelodysplastic syndrome and liver cirrhosis[J]. Ann Lab Med, 2019, 39(2): 218-222. DOI: 10.3343/alm.2019.39.2.218.
[17]	ARORA V, MAIWALL R, RAJAN V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure[J]. Hepatology, 2020, 71(2): 600-610. DOI: 10.1002/hep.30208.
[18]	MOORE K, JAMIL K, VERLEGER K, et al. Real world treatment patterns and outcomes usingterlipressin in 203 patients with the hepatorenal syndrome[J]. Aliment Pharmacol Ther, 2020, 52(2): 351-358. DOI: 1111/apt.15836.
[19]	ANGELI P, GARCIA-TSAO G, NADIM MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document[J]. J Hepatol, 2019, 71(4): 811-822. DOI: 10.1016/j.jhep.2019.07.002.
[20]	SOLÀ E, SOLÉ C, SIMÓN-TALERO M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial[J]. J Hepatol, 2018, 69(6): 1250-1259. DOI: 10.1016/j.jhep.2018.08.006.
[21]	HIRAMINE Y, UTO H, MAWATARI S, et al. Effect of tolvaptan on the prognosis of patients with hepatic ascites[J]. Hepatol Res, 2019, 49(7): 765-777. DOI: 10.1111/hepr.13337.
[22]	NGUYEN-TAT M, JÄGER J, REY JW, et al. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2[J]. United European Gastroenterol J, 2019, 7(4): 529-537. DOI: 10.1177/2050640619825719.
[23]	QIN YX, LONG FL, MAO DW, et al. Efficacy and safety of norepinephrine combined with albumin versus terlipressin combined with albumin in treatment of type 1 hepatorenal syndrome: A Meta-analysis[J]. J Clin Hepatol, 2019, 35(10): 2266-2271. DOI: 10.3969/j.issn.1001-5256.2019.10.027. 覃艳新, 龙富立, 毛德文, 等. 去甲肾上腺素或特利加压素联合白蛋白治疗1型肝肾综合征效果及安全性比较的Meta分析[J]. 临床肝胆病杂志, 2019, 35(10): 2266-2271. DOI: 10.3969/j.issn.1001-5256.2019.10.027.
[24]	LIU JJ, NIU B. Interpretation and Discussion on the 2017 guidelines for the diagnosis and treatment of cirrhosis ascites and related complications[J]. New Chin Med, 2018, 49(1): 1-5. DOI: 10.3969/j.issn.0253-9802.2018.01.001. 刘建军, 牛蓓. 对2017年《肝硬化腹水及相关并发症的诊疗指南》的解读与商榷[J]. 新医学, 2018, 49(1): 1-5. DOI: 10.3969/j.issn.0253-9802.2018.01.001.
[25]	WEI L, YI WY, LIU ZJ, et al. Clinical significance of B-type natriuretic peptide in patients with liver cirrhosis[J]. Chin J Clin Res, 2017, 20(8): 1076-1077. DOI: 10.13429/j.cnki.cjcr.2017.08.020. 韦玲, 易文轶, 刘正金, 等. 肝硬化患者B型利钠肽检测的临床意义[J]. 中国临床研究, 2017, 20(8): 1076-1077. DOI: 10.13429/j.cnki.cjcr.2017.08.020.
[26]	WONG F, MOORE K, DINGEMANSE J, et al. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome[J]. Hepatology, 2008, 47(1): 160-168. DOI: 10.1002/hep.21940.
[27]	LIU JJ, NIU B. Relationship between pathogenesis of end-stage liver disease and hyponatremia and its countermeasures[J]. Chin J Clin Gastroenterol, 2015, 27(3): 189-192. DOI: 10.3870/lcxh.j.issn.1005-541x.2015.03.21. 刘建军, 牛蓓. 终末期肝病发病机制与低钠血症的关系和对策[J]. 临床消化病杂志, 2015, 27(3): 189-192. DOI: 10.3870/lcxh.j.issn.1005-541x.2015.03.21.

Relative Articles

[1]	Yuxin LIU, Liaoyun ZHANG. Influencing factors for the homing ability of mesenchymal stem cells in end-stage liver disease and optimization measures[J]. Journal of Clinical Hepatology, 2025, 41(3): 561-567. doi: 10.12449/JCH250326
[2]	Yu FENG, Junfeng CHEN, Bingliang LIN. Clinical research advances in mesenchymal stem cells for the treatment of end-stage liver disease[J]. Journal of Clinical Hepatology, 2023, 39(5): 1010-1018. doi: 10.3969/j.issn.1001-5256.2023.05.003
[3]	Yue LIANG, Yonghong HU, Wei LIU, Yongping MU, Jiamei CHEN, Ping LIU. Research advances in bone marrow mesenchymal stem cells and its exosomes in treatment of end-stage liver disease[J]. Journal of Clinical Hepatology, 2022, 38(11): 2643-2648. doi: 10.3969/j.issn.1001-5256.2022.11.041
[4]	Society of Infectious Diseases. Expert consensus on diagnosis and treatment of end-stage liver disease complicated with infections(2021 version)[J]. Journal of Clinical Hepatology, 2022, 38(2): 304-310. doi: 10.3969/j.issn.1001-5256.2022.02.010
[5]	Honglin MA, Jing YANG, Qiu JIN, Run LUO, Jiao LENG, Xia WANG. Current status of research on nutritional support in end-stage liver disease[J]. Journal of Clinical Hepatology, 2022, 38(1): 215-219. doi: 10.3969/j.issn.1001-5256.2022.01.038
[6]	Lu YANG, Ye XIONG, Jianrong HUANG. Application of human serum albumin in the management of end-stage liver disease[J]. Journal of Clinical Hepatology, 2022, 38(4): 936-941. doi: 10.3969/j.issn.1001-5256.2022.04.040
[7]	Ming YANG, Yuan HUANG, Lai WEI. Treatment and management of patients with end-stage liver cirrhosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 31-35. doi: 10.3969/j.issn.1001-5256.2021.01.007
[8]	Nan GENG, Ming KONG, Yu CHEN, Zhongping DUAN. Value of L3 skeletal muscle index in nutritional diagnosis of end-stage liver disease[J]. Journal of Clinical Hepatology, 2021, 37(10): 2493-2496. doi: 10.3969/j.issn.1001-5256.2021.10.050
[9]	Qin ZHAO, Junjie YANG, Yanping ZHONG, Shan LI, Yuanyuan LIU, Xu LEI, Long LIU, Huabing TAN. Association between myostatin and sarcopenia in end-stage liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2692-2700. doi: 10.3969/j.issn.1001-5256.2021.11.045
[10]	CHEN WenJi, LIANG Wei, ZHOU YongJian. Acute kidney injury and hepatorenal syndrome in end-stage liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2423-2428. doi: 10.3969/j.issn.1001-5256.2020.11.006
[11]	Li DongCeng, Kong Ming, Chen Yu. Association between end-stage liver disease and sarcopenia[J]. Journal of Clinical Hepatology, 2020, 36(3): 693-696. doi: 10.3969/j.issn.1001-5256.2020.03.050
[12]	LI XiaoYun, HUA Jing. Treatment of hepatorenal syndrome:Vasoconstriction or vasodilation?[J]. Journal of Clinical Hepatology, 2020, 36(11): 2419-2422. doi: 10.3969/j.issn.1001-5256.2020.11.005
[13]	Zhang YiTong, Xin Lei, Li ZhaoShen. Research advances in mesenchymal stem cells in treatment of end-stage liver disease and their application prospect[J]. Journal of Clinical Hepatology, 2019, 35(9): 2104-2107. doi: 10.3969/j.issn.1001-5256.2019.09.049
[14]	Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Gastroenterology, Chinese Medical Association. Clinical guidelines on nutrition in end-stage liver disease[J]. Journal of Clinical Hepatology, 2019, 35(6): 1222-1230. doi: 10.3969/j.issn.1001-5256.2019.06.010
[15]	Society of Infectious Diseases, Chinese Medical Association. Expert consensus on diagnosis and treatment of end-stage liver disease complicated with infections[J]. Journal of Clinical Hepatology, 2018, 34(9): 1862-1872. doi: 10.3969/j.issn.1001-5256.2018.09.008
[16]	Zhu Bin, Zou CongCong, Zheng Xin. Malnutrition assessment and nutrition support therapy for end-stage liver disease[J]. Journal of Clinical Hepatology, 2017, 33(9): 1699-1706. doi: 10.3969/j.issn.1001-5256.2017.09.014
[19]	Chen Si, Sun ZhangYu, Zhang ZhiHao, Wang YingYing. Therapeutic effect of terlipressin combined with albumin in 24 patients with hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2014, 30(8): 782-784. doi: 10.3969/j.issn.1001-5256.2014.08.021
[20]	Chen LiHong, Hu NaiZhong, Wang YaLei. The value of MESO (MELD/Na index) scoring system in predicting prognosis of patients with cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1044-1046+1054.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	朱庆华，高成斌，刘建青，刘广林，刘建军. 肝硬化腹水低钠血症与精氨酸加压素关系和V2受体拮抗剂应用的争议问题. 胃肠病学和肝病学杂志. 2023(12): 1419-1422 .
2.	刘建军，郑文凯，高廷廷，王江红，任燕军，刘建国，刘常林. 制订中国知识产权肝硬化腹水和肝肾综合征诊疗指南的必要性和可行性. 中国临床研究. 2023(12): 1875-1880 .
3.	刘建军，郑文凯. 对《特利加压素在肝硬化并发症临床应用的实践指导(2021版)》的质疑与商榷. 肝脏. 2023(11): 1382-1383 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (525) PDF downloads(36)

Vasoactive substance resistance mechanisms in diagnosis and treatment of end-stage liver diseases: Disputes and counter-measurement

DOI: 10.3969/j.issn.1001-5256.2022.10.040